Amphotericin B
- 15 November 1990
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 88 (1) , 151-166
- https://doi.org/10.1080/00325481.1990.11716368
Abstract
Amphotericin B (Fungizone) has the broadest spectrum of any currently available antifungal agent, is fungicidal, and has a rapid onset of action. Thus, there is rarely a question as to whether it is indicated for treatment of a life-threatening fungal infection. However, clinicians are likely to be concerned about its adverse effects. Dr Sarosi reviews available methods of minimizing such effects and suggests dosing regimens for individual fungal diseases.Keywords
This publication has 33 references indexed in Scilit:
- Infections withCryptococcus neoformansin the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1989
- Prevention of Amphotericin B—Induced Renal ImpairmentArchives of internal medicine (1960), 1988
- Effect of Infusion Rate on Amphotericin B-Associated Febrile ReactionsDrug Intelligence & Clinical Pharmacy, 1988
- Controversial Areas in Antifungal Chemotherapy: Short-Course and Combination Therapy with Amphotericin 8Clinical Infectious Diseases, 1987
- Risk factors of ventricular fibrillation during rapid amphotericin B infusionAntimicrobial Agents and Chemotherapy, 1985
- Antifungal Agents Used in Systemic Mycoses Activity and Therapeutic UseDrugs, 1983
- Amphotericin-B-Induced ThrombocytopeniaAnnals of Internal Medicine, 1982
- Strategies in the Treatment of Systemic Fungal InfectionsNew England Journal of Medicine, 1980
- Disseminated Histoplasmosis: Results of Long-Term Follow-upAnnals of Internal Medicine, 1971
- Amphotericin B ToxicityAnnals of Internal Medicine, 1964